HeartMate II trial fully enrolled
This article was originally published in The Gray Sheet
Executive Summary
Thoratec completes enrollment for the bridge-to-transplantation arm of its HeartMate II left ventricular assist system, implanting 133 patients. The May 31 announcement notes recent FDA approval to enroll up to 90 additional patients, which Thoratec says will not impact the timing of a planned PMA submission for the device. Enrollment is ongoing for the 200-patient destination therapy arm of the trial comparing HeartMate II with HeartMate XVE in end-stage heart failure patients who don't qualify for a transplant (1"The Gray Sheet" May 1, 2006, p. 12)...
You may also be interested in...
FDA Expands Inclusion Criteria For WorldHeart LVAS Destination Therapy Trial
FDA has given conditional approval for WorldHeart to modify its pivotal trial of the Novacor implantable heart-assist pump. The changes are expected to accelerate the study, which has moved slowly since its start in 2004
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.